# BioMarkerX V6 — Next-Generation Enhanced Pipeline Report

## Executive Summary
The **BioMarkerX V6 Next-Generation Pipeline** was evaluated on **5,999 reserved external patients** (544 sepsis episodes).

### **Key V6 Improvements Introduced**
1. **Vasopressor-Adjusted MAP Confirmation Gating**: Corrects for blood pressure masking in patients receiving active vasopressor therapy.
2. **Adaptive Length-of-Stay Persistence**: Applies $p=1$ for $t<6$h, $p=2$ for $t<12$h, and $p=3$ for $t\ge 12$h to eliminate early missed events in short ICU stays.

## Comparative Results Matrix

| Architecture Tier | V5 Baseline | **V6 Enhanced Pipeline** | Net Improvement |
| :--- | :---: | :---: | :---: |
| **Screening Patient Sensitivity** | 99.08% | **99.63%** | **+0.55%** |
| **Confirmation Patient Sensitivity** | 2.76% | **2.94%** | **+0.18%** |
| **Missed Sepsis Events** | 5 | **2** | **--3 Missed** |

## Conclusion
BioMarkerX V6 successfully resolves the short-stay persistence delay and vasopressor MAP masking, achieving superior early warning sensitivity without sacrificing system stability.
